Oryzon Genomics, S.A.
ORY.MCDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
vafidemstat
Borderline Personality Disorder
ORY-2001 Low dose
Mild to Moderate Alzheimer's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
vafidemstat | Phase 2 | Borderline Personality Disorder | - | - |
ORY-2001 Low dose | Phase 2 | Mild to Moderate Alzheimer's Disease | - | - |
Frequently asked questions
What is in Oryzon Genomics, S.A.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Oryzon Genomics, S.A.'s (ORY.MC) pipeline across Phase 2. Its lead program is vafidemstat (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Oryzon Genomics, S.A.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Oryzon Genomics, S.A. (ORY.MC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ORY.MC biotech catalysts?→
Add ORY.MC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Oryzon Genomics, S.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.